Genentech inked a collaboration and license agreement with DualityBio centered on the DUPAC platform for next-generation ADCs aimed at topoisomerase-1 resistance. DualityBio is set to receive $45 million upfront, with milestone payments that could exceed $1 billion across programs, while Genentech takes over global later-stage development and commercialization. The deal targets a known clinical bottleneck as ADCs move earlier in therapy lines and more patients progress after topoisomerase inhibitor–based payloads, increasing demand for payload architectures designed to retain potency under resistance pressure.